KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 5, 2015, Pages 963-969.e4

  Eshleman, James R ^a   Norris, Alexis L ^a   Sadakari, Yoshihiko ^a   Debeljak, Marija ^a   Borges, Michael ^a   Harrington, Colleen ^a   Lin, Elaine ^a   Brant, Aaron ^a   Barkley, Thomas ^a   Almario, J Alejandro ^a   Topazian, Mark ^b   Farrell, James ^c   Syngal, Sapna ^d   Lee, Jeffrey H ^e   Yu, Jun ^a   Hruban, Ralph H ^a   Kanda, Mitsuro ^a   Canto, Marcia Irene ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MAYO CLINIC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Early detection; EUS; Screening

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; K RAS PROTEIN; SECRETIN; CARRIER PROTEIN; DNA; KRAS PROTEIN, HUMAN; NUBP1 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN;

ADULT; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DUODENUM; ENDOSCOPIC ECHOGRAPHY; FAMILY HISTORY; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREAS CYST; PANCREAS JUICE; PANCREATITIS; PYROSEQUENCING; AGED; CHEMISTRY; DNA SEQUENCE; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; TRANSITION TEMPERATURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; DNA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; SEQUENCE ANALYSIS, DNA; TRANSITION TEMPERATURE;

EID: 84927912038     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.11.028     Document Type: Article

References (30)

1. Rahib L., Smith B.D., Aizenberg R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014, 74:2913-2921.
2. Ferrone C.R., Pieretti-Vanmarcke R., Bloom J.P., et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 2012, 152:S43-S49.
3. Shi C., Hruban R.H. Intraductal papillary mucinous neoplasm. Hum Pathol 2012, 43:1-16.
4. Kozuka S., Sassa R., Taki T., et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979, 43:1418-1428.
5. Andea A., Sarkar F., Adsay V.N. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003, 16:996-1006.
6. Shi C., Klein A.P., Goggins M., et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009, 15:7737-7743.
7. Brune K., Abe T., Canto M., et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. AmJ Surg Pathol 2006, 30:1067-1076.
8. Laffan T.A., Horton K.M., Klein A.P., et al. Prevalence of unsuspected pancreatic cysts on MDCT. Am J Radiol 2008, 191:802-807.
9. de Jong K., Nio C.Y., Hermans J.J., et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol 2010, 8:806-811.
10. Canto M.I., Hruban R.H., Fishman E.K., et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012, 142:796-804.
11. Khashab M.A., Yong E., Lennon A.M., et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011, 73:691-696.
12. Hruban R.H., Maitra A., Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008, 1:306-316.
13. Wu J., Matthaei H., Maitra A., et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011, 3:92ra66.
14. Kanda M., Knight S., Topazian M., et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013, 62:1024-1033.
15. Kanda M., Sadakari Y., Borges M., et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 2013, 11:719-730.
16. Bruno M.J. Early diagnosis of pancreatic cancer; looking for a needle in a haystack?. Gut 2013, 62:955-956.
17. Kanda M., Matthaei H., Wu J., et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012, 142:730-733.e9.
18. Hong S.M., Vincent A., Kanda M., et al. Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Clin Cancer Res 2012, 18:4303-4312.
19. Schonleben F., Qiu W., Bruckman K.C., et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett 2007, 249:242-248.
20. Nikiforova M.N., Khalid A., Fasanella K.E., et al. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol 2013, 26:1478-1487.
21. Terhune P.G., Phifer D.M., Tosteson T.D., et al. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev 1998, 7:515-521.
22. Shi C., Fukushima N., Abe T., et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 2008, 7:353-360.
23. Yan L., McFaul C., Howes N., et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005, 128:2124-2130.
24. Lohr M., Muller P., Mora J., et al. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis. Gastrointest Endosc 2001, 53:734-743.
25. Watanabe H., Ha A., Hu Y.X., et al. K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma. Cancer 1999, 86:1441-1448.
26. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006, 4:766-781.
27. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
28. Sikkens E.C., Cahen D.L., de Wit J., et al. Aprospective assessment of the natural course of the exocrine pancreatic function in patients with a pancreatic head tumor. JClin Gastroenterol 2014, 48:e43-e46.
29. Sadakari Y., Kanda M., Maitani K., et al. Mutant KRAS and GNAS DNA concentrations in secretin-stimulated pancreatic fluid collected from the pancreatic duct and the duodenal lumen. Clin Transl Gastroenterol 2014, 5:e62.
30. Takano S., Fukasawa M., Maekawa S., et al. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS One 2014, 9:e98718.